For research use only
| Cat No. | ABC-X0346C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocytes |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
Human PIK3CA (H1047L) BAF3 Cell Line, PIK3CA, BAF3, Overexpression Stable Cell Lines, Transfected Stable Cell Lines
Human PIK3CA (H1047L) BAF3 Overexpression Cell Line is a genetically engineered model derived from selected murine BAF3 pro-B cell line based on customers’ requirement. PIK3CA (H1047L) BAF3 overexpression cell line is generated by stable integration of exogenous human PIK3CA mutant (H1047L) into BAF3 host cells using lentiviral vector delivery. The edited cells are maintained at low passage numbers (<P20). Overexpression clone is validated at gene level by qRT-PCR. Target PIK3CA encodes the catalytic subunit p110α of PI3K, a key regulator of the PI3K/AKT pathway. The H1047L mutation is a well-characterized oncogenic driver in breast, colon, and endometrial cancers, leading to constitutive pathway activation. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0346C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocytes |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO2 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
This model enables the investigation of oncogenic PIK3CA signaling via the H1047L mutation, a well-known hotspot in breast and endometrial cancers. It facilitates studies on constitutive PI3K activation, resistance to PI3K-targeted therapies, and pathway crosstalk with mTOR signaling. This cell line is ideal for screening pathway-specific inhibitors, assessing therapeutic efficacy, and dissecting mechanisms of cell proliferation and survival under cytokine-independent growth conditions.